Headspace Smartphone Application for Endometrial Cancer
This trial will test whether the Headspace smartphone app can help reduce stress in patients with endometrial or cervical cancer.
- Endometrial Cancer
- Gynecologic Cancers
- Cervical Cancer
- Quality of Life
- Opioid Use Disorder
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Are there open spots for participants in this scientific experiment?
"Affirmative. Clinicaltrials.gov indicates that this medical study, which originated on July 25th 2020, is currently enrolling patients and looking to recruit 120 participants from a single location."
How many subjects are partaking in this experiment?
"That is correct. Referring to clinicaltrials.gov, we can see that the trial was first put up on July 25th 2020 and it has been recently updated on February 18th 2022. The research project requires 120 individuals from a single centre."
What key goals is this research endeavor attempting to achieve?
"This clinical trial will be evaluated over a time-frame extending from enrolment to 6 weeks after treatment for [cervical cancer](https://www.withpower.com/clinical-trials/cervical-cancer), and opiate usage in endometrial cancer. Secondary objectives include the completion of Functional Assessment of Cancer Therapy-General forms at various points during the study, patient satisfaction surveys, and monitoring complication rates among both groups."
Is the upper age limit for this experimentation open to those over 45 years old?
"This experiment is inviting volunteers aged 18 and older, but no more than 90 years old."
Who has the opportunity to be a participant in this investigation?
"Criteria for enrollment in this clinical trial is strict: the patient must have endometrial neoplasms and be between 18-90 years old. The team behind this study hopes to recruit roughly 120 patients."